Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals (NASDAQ: VRTX) is modeling right now.

Thanks to its long-standing dominance in a key niche market, its newfound pursuit of powerful gene therapies, and its cash output, there's good reason to be excited about the stock. So here are three arguments for why it's worth buying now.

Vertex's sales are highly recurring because it makes medicines that patients need to take consistently to manage their chronic symptoms. Specifically, it makes four different drugs to treat cystic fibrosis (CF), a hereditary lung disease affecting around 88,000 people in the Western world, and it has even more in development.

Continue reading

Source Fool.com